GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mycenax Biotech Inc (ROCO:4726) » Definitions » Additional Paid-In Capital

Mycenax Biotech (ROCO:4726) Additional Paid-In Capital : NT$423.3 Mil(As of Mar. 2025)


View and export this data going back to 2013. Start your Free Trial

What is Mycenax Biotech Additional Paid-In Capital?


Mycenax Biotech's quarterly additional paid-in capital increased from Sep. 2024 (NT$415.7 Mil) to Dec. 2024 (NT$421.1 Mil) and increased from Dec. 2024 (NT$421.1 Mil) to Mar. 2025 (NT$423.3 Mil).

Mycenax Biotech's annual additional paid-in capital declined from Dec. 2022 (NT$1,468.1 Mil) to Dec. 2023 (NT$1,074.3 Mil) and declined from Dec. 2023 (NT$1,074.3 Mil) to Dec. 2024 (NT$421.1 Mil).


Mycenax Biotech Additional Paid-In Capital Historical Data

The historical data trend for Mycenax Biotech's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mycenax Biotech Additional Paid-In Capital Chart

Mycenax Biotech Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Additional Paid-In Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only 53.11 576.95 1,468.14 1,074.29 421.11

Mycenax Biotech Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,077.67 401.08 415.70 421.11 423.33

Mycenax Biotech Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

Mycenax Biotech Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Mycenax Biotech's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.


Mycenax Biotech Business Description

Traded in Other Exchanges
N/A
Address
No.66, Shengyi 2nd Road, 7th Floor, Hsinchu Science Park, Hsinchu County, Zhubei, TWN, 302041
Mycenax Biotech Inc is a Taiwan-based biopharmaceutical company. It is engaged in the development and manufacture of biopharmaceutical products, specializing in mammalian and microbial cell-derived biologics. The company provides services for program evaluation/confirmation, cell line development, and construction, process development technology platforms, drug characterization analysis, the establishment of testing methods, and drug production in accordance with PIC/S GMP manufacturing standards.

Mycenax Biotech Headlines

No Headlines